🟢 Absci Corp is trading 6.7% up today as Leerink highlights AI-native biologics pipeline

Absci Corp is trading 6.7% up at $7.47 after new analyst commentary and AI-themed visibility boosted sentiment around its drug discovery platform.

• Leerink highlighted the company’s AI-native, clinical-stage biologics pipeline and estimated a fair value of $8.11, implying significant upside from recent price levels.
• Investor attention is increasingly focused on upcoming clinical data for ABS-201, which serves as a key catalyst for the platform.
• The move extends the stock’s recent rebound and ongoing rerating following a series of positive analyst reports and price target increases.